drugset / Trial / NCT00830245
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Phase 2
Terminated
20 enrolled
Clinical Research Center for Solid Tumor, Korea
Korean Cancer Study Group · collabSeoul National University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis
Timeline
- Start
- 2009-01
- Primary completion
- 2011-07
- Completion
- 2011-07
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | — |